Sutro Biopharma
STRO
86 hedge funds and large institutions have $304M invested in Sutro Biopharma in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 16 reducing their positions, and 11 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 16
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
61% more capital invested
Capital invested by funds: $189M → $304M (+$115M)
8% more funds holding
Funds holding: 80 → 86 (+6)
1.72% more ownership
Funds ownership: 6.79% → 8.51% (+1.7%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.1M |
| 2 |
BlackRock
New York
|
+$10.3M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$6.79M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.61M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.81M |
| 2 |
Renaissance Technologies
New York
|
-$1.16M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.15M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$486K |
| 5 |
Bessemer Group
Woodbridge,
New Jersey
|
-$374K |
STRO Hedge Fund Activity: Q3 2020 in Review
86 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2020, worth a combined $304M — up 61% from $189M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new STRO positions and 11 closed out — a net gain of 7 holders — while 40 added to existing stakes and 16 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $12.1M. The largest seller was Logos Global Management, exiting entirely with an estimated $2.81M sold.
- 86 institutional investors held Sutro Biopharma (STRO) as of Q3 2020, up from 80 in Q2 2020.
- Funds reported $304M of Sutro Biopharma stock for Q3 2020, up 61% quarter-over-quarter.
- 18 funds opened new Sutro Biopharma positions in Q3 2020 and 11 closed out, a net change of +7 holders.
- The largest Sutro Biopharma buyer in Q3 2020 was EcoR1 Capital, an estimated $12.1M added.
- The largest Sutro Biopharma seller in Q3 2020 was Logos Global Management, an estimated $2.81M sold.
Based on aggregated 13F filings for Q3 2020.